VeruVERU +2.21%28 PB Ratio is 1.38 as of Jun. 28, 2026, which is 53% below its 10-year median of 2.96. GuruFocus rates VERU with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, Veru ranks better than 73.3% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-28), Veru's share price is $3.00. Veru's Book Value per Share for the quarter that ended in Mar. 2026 was $2.17. Hence, Veru's PB Ratio of today is 1.38.
The historical rank and industry rank for Veru's PB Ratio or its related term are showing as below:
VERU'
s PB Ratio Range Over the Past 10 Years
Min: 0.72 Med: 2.96 Max: 30.65
Current: 1.38
During the past 13 years, Veru's highest PB Ratio was 30.65. The lowest was 0.72. And the median was 2.96.
VERU's PB Ratio is ranked better than 73.3% of 1232
companies
in the Biotechnology industry
Industry Median: 2.815
vs VERU: 1.38
During the past 12 months, Veru's average Book Value Per Share Growth Rate was 50.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -50.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -33.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -16.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Veru was 211.70% per year. The lowest was -78.10% per year. And the median was 6.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Veru PB Ratio Related Terms
Veru PB Ratio Historical Data
* Premium members only.
The historical data trend for Veru's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Veru's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veru PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veru's PB Ratio distribution charts can be found below:
* The bar in red indicates where Veru's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Veru's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Veru (VERU) has a PB Ratio of 1.38 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Veru and its competitors. This is 53% below median its historical median of 2.96. Over the past decade, Veru's PB Ratio has ranged from 0.72 to 30.65. According to the industry distribution chart, Veru ranks #329 out of 1232 companies in the Biotechnology industry, placing it in the top 26.7%.
Is Veru's PB Ratio too high?
Veru's current PB Ratio of 1.38 is 53% below median its 10-year median of 2.96. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 30.65. The Biotechnology industry median PB Ratio is 2.82. Veru's value of 1.38 is 51% below this industry median. Based on the distribution chart, Veru ranks #329 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Veru has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Veru's PB Ratio compare to INMB and GRDX?
According to the Biotechnology industry distribution chart, Veru ranks #329 out of 1232 companies for PB Ratio. This puts Veru in the upper half of its industry. The industry median PB Ratio is 2.82. Veru's value of 1.38 is 51% below this benchmark. Historically, Veru's own PB Ratio has ranged from 0.72 to 30.65 over the past decade. While the company's 10-year median is 2.96 vs. the industry median of 2.82, Veru has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veru's current PB Ratio of 1.38 is 51% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Veru and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veru's current PB Ratio is 1.38, which is 53% below median its own 10-year median of 2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veru stock overvalued right now?
Veru (VERU) has a current PB Ratio of 1.38. The current PB Ratio is 1.38, which is 53% below median its 10-year median of 2.96 and 51% below the Biotechnology industry median of 2.82. Veru's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Veru (VERU), the current PB Ratio is 1.38 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
28GF Score
Get the complete analysis for VERU
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VERU has been successfully added to your 
